Thu, June 12, 2025
Wed, June 11, 2025
Tue, June 10, 2025
Mon, June 9, 2025
Sun, June 8, 2025
Sat, June 7, 2025
Fri, June 6, 2025
Thu, June 5, 2025
Wed, June 4, 2025
Tue, June 3, 2025
Mon, June 2, 2025

A cautious culture cost Novo its obesity lead

  Copy link into your clipboard //science-technology.news-articles.net/content/2 .. cautious-culture-cost-novo-its-obesity-lead.html
  Print publication without navigation Published in Science and Technology on by STAT
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
And more biotech news updates, brought to you by The Readout.
The article from STAT News dated June 5, 2025, discusses several significant developments in the biotech industry. Novo Nordisk is set to acquire Vigil Neuroscience for $1.5 billion, aiming to bolster its neuroscience portfolio. Merck is facing challenges with its blockbuster cancer drug Keytruda, as a new study suggests it may not be as effective in certain patient populations as previously thought. Eli Lilly is expanding its manufacturing capabilities to meet the growing demand for its diabetes and obesity treatments. Lastly, REGENXBIO reported positive results from a Phase II trial of its gene therapy for Duchenne muscular dystrophy, sparking optimism about future treatments for the condition.

Read the Full STAT Article at:
[ https://www.statnews.com/2025/06/05/biotech-news-novo-nordisk-vigil-merck-eli-lilly-regenxbio-keytruda-the-readout/ ]